New PET tracer aims to reveal hidden Hormone-Making tumors
NCT ID NCT06246357
First seen Jun 24, 2026 · Last updated Jun 30, 2026 · Updated 4 times
Summary
This phase 2 study tests a radioactive tracer called [68Ga]Ga-PentixaFor to see if it can better identify adrenal tumors that produce excess hormones like aldosterone or cortisol. About 80 adults with known adrenal tumors and high hormone levels will receive the tracer before a PET scan. The goal is to improve diagnosis of functional adrenal tumors, which could guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[68Ga]Ga-PentixaFor (a radioactive tracer)
What this could lead to
If successful, this tracer could make it easier to identify which adrenal tumors are producing excess hormones, helping doctors choose the right treatment.
What could go wrong
This is an early phase 2 study with only 80 participants, so results may not apply to everyone. The tracer is still experimental and its accuracy needs further validation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY ALDOSTERONISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••